MAP2K7 and cutaneous melanoma: Randomised prospective trial data support the use of combination ICIs as the first-line treatment for advanced non-resectable cutaneous melanoma, showing improvements in overall survival and progression-free survival compared with patients treated initially with BRAF/MEK inhibitors [53,54].